<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="2935"><DrugName>didanosine</DrugName><DrugNamesKey><Name id="42754286">Videx</Name><Name id="42764988">Videx EC</Name><Name id="42754283">didanosine</Name></DrugNamesKey><DrugSynonyms><Name><Value>BMY-40900</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ddI</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>didanosine</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>dideoxyinosine</Value></Name><Name><Value>NSC-612049</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Videx</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Videx EC</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>69655-05-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20518">National Institutes of Health</CompanyOriginator><CompaniesPrimary><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesPrimary><CompaniesSecondary><Company id="20518">National Institutes of Health</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2935" type="Drug"><TargetEntity id="143041" type="siDrug">Didanosine</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity></SourceEntity><SourceEntity id="345" type="Action"><TargetEntity id="486" type="Mechanism">Reverse Transcriptase Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>HIV infection - US - Dec-1991</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="158">HIV infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="1016">HIV-1 reverse transcriptase inhibitor</Action><Action id="345">Reverse transcriptase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="595">Tablet formulation</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="680">Buccal formulation systemic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-07T12:02:40.000Z</LastModificationDate><ChangeDateLast>2019-06-28T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Didanosine (Videx) is a synthetic purine nucleoside analog reverse transcriptase inhibitor that has been developed and launched by &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS), under license from the &lt;ulink linkID="20518" linkType="Company"&gt;National Institutes of Health&lt;/ulink&gt;. Didanosine, in combination with other antiretroviral drugs, is indicated for the treatment of HIV infection in adults and children [&lt;ulink linkID="482191" linkType="Reference"&gt;482191&lt;/ulink&gt;], [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was first launched in 1991 and is available as an oral solution, a reduced-mass tablet and an enteric-coated capsule formulation [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;], [&lt;ulink linkID="553873" linkType="Reference"&gt;553873&lt;/ulink&gt;]. BMS has also launched chewable/dispersible buffered tablets, 35% smaller than the tablet originally marketed [&lt;ulink linkID="215822" linkType="Reference"&gt;215822&lt;/ulink&gt;]. By October 1994, the drug had been launched in Japan [&lt;ulink linkID="165739" linkType="Reference"&gt;165739&lt;/ulink&gt;].    In August 2000, the drug was approved in the Netherlands [&lt;ulink linkID="1434238" linkType="Reference"&gt;1434238&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="1434240" linkType="Reference"&gt;1434240&lt;/ulink&gt;]. In September 2000, the drug was approved in Ireland and subsequently launched [&lt;ulink linkID="1405066" linkType="Reference"&gt;1405066&lt;/ulink&gt;]. In January 2003, the drug was launched in Sweden [&lt;ulink linkID="1412213" linkType="Reference"&gt;1412213&lt;/ulink&gt;].  In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1382555" linkType="Reference"&gt;1382555&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;BMS stated that there was no issued patent covering the Videx EC formulation [&lt;ulink linkID="591537" linkType="Reference"&gt;591537&lt;/ulink&gt;]. The NIH's method of use patent, licensed by BMS, expired in 2007 in the US (which included a pediatric extension) and Japan. In Europe, the use patent was granted in Austria, Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Sweden and the UK.  Expiration of this use patent in the EU occurred between 2006 and 2009 on a country-by-country basis. The method of use patent was not obtained in Denmark, Finland, Greece, Portugal or Spain [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;]. The license of the NIH method of use patent was not exclusive, allowing another company to license and obtain approval for marketing [&lt;ulink linkID="591537" linkType="Reference"&gt;591537&lt;/ulink&gt;]. BMS has patents covering a particular reduced mass formulation in the US, EU and Japan that expire in 2012, and pending patent applications that cover the enteric-coated formulation in the US,  EU and Japan. If these patents issue, expiration will be in 2018. US data exclusivity for this formulation expired in May 2004 and in Japan in March 2005 [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2004, &lt;ulink linkID="14354" linkType="Company"&gt;Barr Laboratories&lt;/ulink&gt; received approval for its generic version of didanosine delayed-release capsules in 200, 250 and 400 mg doses [&lt;ulink linkID="574415" linkType="Reference"&gt;574415&lt;/ulink&gt;]; the product was launched  in the same month with 180 days of market exclusivity  [&lt;ulink linkID="574415" linkType="Reference"&gt;574415&lt;/ulink&gt;], [&lt;ulink linkID="631515" linkType="Reference"&gt;631515&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2010,  &lt;ulink linkID="1003307" linkType="Company"&gt;Matrix Laboratories&lt;/ulink&gt;'  125, 200, 250 and 400 mg delayed-release capsules were granted FDA approval under the President's Emergency Plan for AIDS Relief; the generic was to be launched in the US in 2Q10, and sold in a number of developing countries [&lt;ulink linkID="1091574" linkType="Reference"&gt;1091574&lt;/ulink&gt;]. In June 2011, BMS, under its Global Access Program, signed an immunity-from-suit agreement with Matrix, allowing Matrix to supply generic didanosine, including pediatric formulations, in sub-Saharan Africa and India [&lt;ulink linkID="1204082" linkType="Reference"&gt;1204082&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt; In  October 1991 the drug was approved in the US [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;].The drug was first launched in 1991. In February 1996, the FDA's antiviral drugs advisory committee voted unanimously for the use of didanosine as a first-line therapy in HIV infection; it had previously only been used in the second line. It showed a 50% drop in the risk of death, compared with &lt;ulink linkID="16453" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="16453" linkType="Company"&gt;Glaxo Wellcome&lt;/ulink&gt;'s &lt;ulink linkID="44316" linkType="Drug"&gt;zidovudine&lt;/ulink&gt;, based on the ACTG 175 study results [&lt;ulink linkID="207243" linkType="Reference"&gt;207243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 1993, the drug was approved in Belgium [&lt;ulink linkID="1449718" linkType="Reference"&gt;1449718&lt;/ulink&gt;]; by May 2018, BMS had withdrawn the drug in Belgium [&lt;ulink linkID="2126901" linkType="Reference"&gt;2126901&lt;/ulink&gt;]. In August 2000, the drug was approved in the Netherlands [&lt;ulink linkID="1434238" linkType="Reference"&gt;1434238&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="1434240" linkType="Reference"&gt;1434240&lt;/ulink&gt;]. In September 2000, the drug was approved in Ireland and subsequently launched [&lt;ulink linkID="1405066" linkType="Reference"&gt;1405066&lt;/ulink&gt;]. In January 2003, the drug was launched in Sweden [&lt;ulink linkID="1412213" linkType="Reference"&gt;1412213&lt;/ulink&gt;].   In March 2003, the drug was launched in Norway [&lt;ulink linkID="1458971" linkType="Reference"&gt;1458971&lt;/ulink&gt;]. In  June 2006, the drug was launched in Denmark [&lt;ulink linkID="1423713" linkType="Reference"&gt;1423713&lt;/ulink&gt;].   In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1382555" linkType="Reference"&gt;1382555&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2001, the drug was launched in Switzerland by BMS [&lt;ulink linkID="1615527" linkType="Reference"&gt;1615527&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;By October 1994, the drug had been launched in Japan [&lt;ulink linkID="165739" linkType="Reference"&gt;165739&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In April 2006, the drug was launched in China [&lt;ulink linkID="1290650" linkType="Reference"&gt;1290650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By October 1994, the drug had been launched in Canada [&lt;ulink linkID="165739" linkType="Reference"&gt;165739&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In October 1992, the drug was approved as Videx chewable buffered tablets in Taiwan. It is indicated as a second-line treatment of HIV infection in patients who fail AZT treatment or are intolerable to side effects of AZT. The product was assumed to be launched shortly after its approval there [&lt;ulink linkID="1530186" linkType="Reference"&gt;1530186&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 1994, the drug had been launched in  Australia [&lt;ulink linkID="165739" linkType="Reference"&gt;165739&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 1994, the drug had been launched in New Zealand [&lt;ulink linkID="165739" linkType="Reference"&gt;165739&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 1994, the drug had been launched in Hong Kong [&lt;ulink linkID="165739" linkType="Reference"&gt;165739&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By April 2013, the drug had been approved in Brazil as Videx EC [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;]. By November 2017, the drug had been launched in Brazil [&lt;ulink linkID="2126909" linkType="Reference"&gt;2126909&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;Didanosine carries a black box warning stating the risk of potentially life-threatening complications such as pancreatitis, lactic acidosis and liver problems [&lt;ulink linkID="482191" linkType="Reference"&gt;482191&lt;/ulink&gt;]. By May 2009, the FDA had issued an Early Communication following the release of data from an observational study (the D:A:D study) that suggested an increased risk of myocardial infarction in patients receiving didanosine. At that time, the FDA was conducting a review of the data [&lt;ulink linkID="1060760" linkType="Reference"&gt;1060760&lt;/ulink&gt;].  In February 2010, the FDA issued a safety warning of a potential risk of non-cirrhotic portal hypertension in patients treated with didanosine; the drug label was subsequently revised to include information about NCPH. The FDA evaluation concluded that in certain HIV patients the benefits of didanosine outweigh its risks [&lt;ulink linkID="1072275" linkType="Reference"&gt;1072275&lt;/ulink&gt;]. By August 2015, the US label had carried a black boxed warning highlighting the increased risk of pancreatitis, lactic acidosis and hepatomegaly with steatosis [&lt;ulink linkID="482191" linkType="Reference"&gt;482191&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase IV&lt;/subtitle&gt;In May 2004, a randomized, multicenter, open-label study (&lt;ulink linkID="13448" linkType="Protocol"&gt;NCT00214435&lt;/ulink&gt;; TEddI) in well-controlled treatment-experienced HIV-infected patients (expected n = 120), was initiated. The trial would assess compliance with a qd regimen of lamivudine, efavirenz and didanosine   versus continuation of current anti-retroviral regimen delivered at least bid. In October 2005, the study was still recruiting [&lt;ulink linkID="1107349" linkType="Reference"&gt;1107349&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2002, a non-randomized, uncontrolled,  open-label, phase IV study (&lt;ulink linkID="13642" linkType="Protocol"&gt;NCT00116415&lt;/ulink&gt;; DART I) was initiated in patients with HIV. Participants (expected n = 65) would receive a once daily regimen of didanosine (ddl), &lt;ulink linkID="10172" linkType="Drug"&gt;efavirenz&lt;/ulink&gt; (EFV) and &lt;ulink linkID="3474" linkType="Drug"&gt;lamivudine&lt;/ulink&gt; (3TC). The primary endpoint was improved outcomes, as measured by viral load, CD4 counts and adherence. The trial was completed in November 2004 [&lt;ulink linkID="1107340" linkType="Reference"&gt;1107340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In November 1999, a study  (&lt;ulink linkID="8649" linkType="Protocol"&gt;NCT00000637&lt;/ulink&gt;; ACTG 152) to compare the effectiveness of treatment with &lt;ulink linkID="44316" linkType="Drug"&gt;zidovudine&lt;/ulink&gt; (AZT) compared to didanosine (ddI) and compared to the combination of AZT and ddI as determined by survival and disease progression, was initiated. The   phase III, randomized, double-blind trial  enrolled 819 patients, and was completed by December 2005 [&lt;ulink linkID="1107465" linkType="Reference"&gt;1107465&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In July 1999,  a randomized, open-label,  phase III study  (&lt;ulink linkID="12610" linkType="Protocol"&gt;NCT00002429&lt;/ulink&gt;; AI454-152) to compare the efficacy of an anti-HIV triple drug combination  regimen containing didanosine (ddI) enteric coated (EC) formulation, stavudine (d4T) and nelfinavir (NFV)  versus a typical anti-HIV drug regimen containing &lt;ulink linkID="16696" linkType="Drug"&gt;Combivir&lt;/ulink&gt; (lamivudine + zidovudine) and NFV, was initiated. Patients (estimated n = 500) were to be  randomized to one  of two groups for 48 weeks of open-label treatment. Antiviral activity would be  determined by the proportion of patients with HIV RNA levels of &amp;lt; 400 copies/ml at week 48. By December 2005, the trial was completed. Results of the study were included in the prescribing information on didanosine; pancreatitis resulting in death was observed in one patient who received didanosine plus stavudine plus nelfinavir, one patient who received didanosine plus stavudine plus indinavir, and 2 of 68 patients who received didanosine plus stavudine plus indinavir plus hydroxyurea [&lt;ulink linkID="536721" linkType="Reference"&gt;536721&lt;/ulink&gt;], [&lt;ulink linkID="1107464" linkType="Reference"&gt;1107464&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 1999, a randomized, open-label, phase III, efficacy study (&lt;ulink linkID="20268" linkType="Protocol"&gt;NCT00002224&lt;/ulink&gt;; AI454-158), to   compare the      effectiveness of didanosine EC versus the standard form of didanosine, was initiated. Both forms of the drug would be given to patients (n = 120) with      &lt;ulink linkID="4481" linkType="Drug"&gt;stavudine&lt;/ulink&gt; (d4T) plus &lt;ulink linkID="8255" linkType="Drug"&gt;nelfinavir&lt;/ulink&gt; (NLF). The trial was completed in March 1999 [&lt;ulink linkID="1107350" linkType="Reference"&gt;1107350&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Studies using didanosine in combination with AZT showed a reduction in the occurrence of AIDS complications than had previously been observed with AZT alone [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2007, a non-randomized, open-label, phase I/II, safety and efficacy study (&lt;ulink linkID="14867" linkType="Protocol"&gt;NCT00364793&lt;/ulink&gt;; AI266-922) was initiated in HIV-infected infants and children 3 months to 6 years of Age (expectedn = 32). The study would  determine the dose of efavirenz in combination with didanosine and &lt;ulink linkID="4728" linkType="Drug"&gt;emtricitabine&lt;/ulink&gt;. In January 2010, the study was recruiting; completion was expected by February 2016 [&lt;ulink linkID="1107466" linkType="Reference"&gt;1107466&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1999, a  multicenter, phase II, double-blind study (&lt;ulink linkID="8657" linkType="Protocol"&gt;NCT00000823&lt;/ulink&gt;; ACTG 276) evaluating differences among various zidovudine/didanosine regimens on quantitative measures of viral burden in relatively early HIV-1 infection, was initiated.   By December 2005, the trial had enrolled 85 participants and  been completed [&lt;ulink linkID="1107467" linkType="Reference"&gt;1107467&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In March 1999, a randomized, active-controlled, open-label, phase I study (&lt;ulink linkID="13204" linkType="Protocol"&gt;NCT00002360&lt;/ulink&gt;; AI454-157) was initiated, to  investigate whether the coated-capsule form of didanosine is as safe and absorbed by the body as well as the chewable-tablet form. Patients (n = 30) would be randomized to 1 of 2 groups to receive treatment on two separate occasions at least 72 h apart. The study was complete by January 2003 [&lt;ulink linkID="1107493" linkType="Reference"&gt;1107493&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1999, a randomized, open-label, phase I/II, safety and efficacy study (&lt;ulink linkID="8853" linkType="Protocol"&gt;NCT00000656&lt;/ulink&gt;; ACTG 143) was initiated. The study would assess the safety and to evaluate the anti-HIV effect of low, moderate and high dose schedules of zidovudine (AZT) plus didanosine (ddI) versus ddI alone in asymptomatic HIV-infected patients (n = 116).  The study was completed in December 2005 [&lt;ulink linkID="1107500" linkType="Reference"&gt;1107500&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1999, a  phase I, open-label study (&lt;ulink linkID="11952" linkType="Protocol"&gt;NCT00000772&lt;/ulink&gt;; ACTG 231) to evaluate the safety, tolerance, and pharmacokinetic interactions of combination didanosine/&lt;ulink linkID="5369" linkType="Drug"&gt;ribavirin&lt;/ulink&gt; in HIV-positive individuals (n = 15), was initiated. Patients receive didanosine alone for 4 weeks, followed by 8 weeks of combination didanosine/ribavirin. The trial was completed by December 2005 [&lt;ulink linkID="1107502" linkType="Reference"&gt;1107502&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In 1996, &lt;ulink linkID="13794" linkType="Company"&gt;Ajinomoto&lt;/ulink&gt; was manufacturing didanosine under license, and supplying it to BMS [&lt;ulink linkID="218569" linkType="Reference"&gt;218569&lt;/ulink&gt;], [&lt;ulink linkID="776938" linkType="Reference"&gt;776938&lt;/ulink&gt;]. In June 2010, Ajinomoto continued to have a capability to manufacture and supply didanosine [&lt;ulink linkID="1108077" linkType="Reference"&gt;1108077&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The enzymatic preparation of didanosine from &lt;ulink linkID="2936" linkType="Drug"&gt;dideoxyadenosine&lt;/ulink&gt; was first described in 1975 [&lt;ulink linkID="213494" linkType="Reference"&gt;213494&lt;/ulink&gt;]. The associated patent, &lt;ulink linkID="IN1475256" linkType="Patent"&gt;US-04861759&lt;/ulink&gt;, claimed its use for the treatment of retroviral infection. Didanosine was also mentioned in an earlier patent from Wellcome, &lt;ulink linkID="IN1166506" linkType="Patent"&gt;EP-00206497&lt;/ulink&gt;. Although the claims of the patent only specified a method for the preparation of didanosine rather than its use, its antiretroviral activity is described in the main part.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="165739" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="165739" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1412213" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-06-19T00:00:00.000Z</StatusDate><Source id="1423713" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-04-11T00:00:00.000Z</StatusDate><Source id="1290650" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-08T00:00:00.000Z</StatusDate><Source id="2126909" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1991-12-31T00:00:00.000Z</StatusDate><Source id="536721" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-01T00:00:00.000Z</StatusDate><Source id="1615527" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-01T00:00:00.000Z</StatusDate><Source id="1458971" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="165739" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="165739" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="1405066" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-12-31T00:00:00.000Z</StatusDate><Source id="1530186" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-21T00:00:00.000Z</StatusDate><Source id="1382555" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="165739" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="1434240" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-18T00:00:00.000Z</StatusDate><Source id="2126901" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="166694" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-09-15T00:00:00.000Z</StatusDate><Source id="1405066" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-08-17T00:00:00.000Z</StatusDate><Source id="1434238" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-10-09T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-10-23T00:00:00.000Z</StatusDate><Source id="1530186" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1993-04-01T00:00:00.000Z</StatusDate><Source id="1449718" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-04-30T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15065">Bristol-Myers Squibb Co</OwnerCompany><Country id="US">US</Country><Indication id="158">HIV infection</Indication><AwardedIndication>Treatment of acquired immunodeficiency syndrome.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-06-22T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20518">National Institutes of Health</OwnerCompany><Country id="US">US</Country><Indication id="158">HIV infection</Indication><AwardedIndication>Treatment of aquired immunodeficiency syndrome.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1987-07-21T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00940"><Name>HIV-1 reverse transcriptase</Name><SwissprotNumbers><Swissprot>P03366</Swissprot><Swissprot>P03367</Swissprot><Swissprot>P03369</Swissprot><Swissprot>P04585</Swissprot><Swissprot>P04586</Swissprot><Swissprot>P04587</Swissprot><Swissprot>P04588</Swissprot><Swissprot>P04589</Swissprot><Swissprot>P05959</Swissprot><Swissprot>P05960</Swissprot><Swissprot>P05961</Swissprot><Swissprot>P12497</Swissprot><Swissprot>P12498</Swissprot><Swissprot>P12499</Swissprot><Swissprot>P18802</Swissprot><Swissprot>P20875</Swissprot><Swissprot>P20892</Swissprot><Swissprot>P24740</Swissprot><Swissprot>P35963</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01684"><Name>Reverse transcriptase</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>18 references added [&lt;ulink url="utility.reference?i_reference_id=2103760" linkType="reference" linkID="2103760"&gt;2103760&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=475353" linkType="reference" linkID="475353"&gt;475353&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2102974" linkType="reference" linkID="2102974"&gt;2102974&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=553563" linkType="reference" linkID="553563"&gt;553563&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=870060" linkType="reference" linkID="870060"&gt;870060&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1754964" linkType="reference" linkID="1754964"&gt;1754964&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1102722" linkType="reference" linkID="1102722"&gt;1102722&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2103756" linkType="reference" linkID="2103756"&gt;2103756&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2072602" linkType="reference" linkID="2072602"&gt;2072602&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2017718" linkType="reference" linkID="2017718"&gt;2017718&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1984568" linkType="reference" linkID="1984568"&gt;1984568&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1103059" linkType="reference" linkID="1103059"&gt;1103059&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2012257" linkType="reference" linkID="2012257"&gt;2012257&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2003488" linkType="reference" linkID="2003488"&gt;2003488&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1748678" linkType="reference" linkID="1748678"&gt;1748678&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1102815" linkType="reference" linkID="1102815"&gt;1102815&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2087942" linkType="reference" linkID="2087942"&gt;2087942&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2009903" linkType="reference" linkID="2009903"&gt;2009903&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="13794">Ajinomoto Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1[nH]c2c(c(=O)n1)ncn2[C@H]3CC[C@H](O3)CO</Smiles></StructureSmiles><Deals><Deal id="118470" title="Bristol-Myers Squibb to develop the National Institutes of Health's Didanosine"></Deal><Deal id="119802" title="Ajinomoto to manufacture didanosine for Bristol-Myers Squibb "></Deal></Deals><PatentFamilies><PatentFamily id="1020085" number="IN-200701677" title="Novel polymorph of didanosine comprises same, and process for preparing crystalline form of didanosine and its salts"></PatentFamily><PatentFamily id="1072120" number="WO-2008124192" title="Novel HIV-1 reverse transcriptase codon deletion and its use in the management and treatment of HIV infections"></PatentFamily><PatentFamily id="1087843" number="WO-09000555" title="Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use."></PatentFamily><PatentFamily id="1088236" number="WO-2008087839" title="Process for production of crystal of purine nucleoside compound"></PatentFamily><PatentFamily id="1088995" number="WO-03014105" title="Bicyclic compound, production and use thereof"></PatentFamily><PatentFamily id="1097049" number="CN-01369267" title="Medicinal composition containing zidovudine and bideoxyinosine"></PatentFamily><PatentFamily id="1133056" number="WO-09947146" title="Anti-HIV combination comprising hydroxyurea, DDI, and a protease inhibitor."></PatentFamily><PatentFamily id="1133058" number="WO-09948504" title="Compositions For Inhibiting Human Immunodeficiency Virus Using Hydroxyurea And A Reverse Transcriptase Inhibitor"></PatentFamily><PatentFamily id="128883" number="WO-09914237" title="Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infections."></PatentFamily><PatentFamily id="1495978" number="WO-09014091" title="Method of treatment of hepatitis."></PatentFamily><PatentFamily id="1504184" number="US-06114312" title="Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor"></PatentFamily><PatentFamily id="1682079" number="US-06607747" title="High drug load acid labile pharmaceutical composition"></PatentFamily><PatentFamily id="171858" number="DE-01079809" title="Enteric Coated Pharmaceutical Composition And Method Of Manufacturing"></PatentFamily><PatentFamily id="1726344" number="WO-09932100" title="Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative."></PatentFamily><PatentFamily id="1751886" number="WO-00112228" title="Compositions for treating viral infections, and methods therefor"></PatentFamily><PatentFamily id="1796696" number="WO-09610399" title="Liposome-formulations for treatment of viral diseases."></PatentFamily><PatentFamily id="180541" number="WO-2006034001" title="Methods of treating hiv infection"></PatentFamily><PatentFamily id="1807163" number="WO-2004098640" title="Use of combinations of reverse transcriptase inhibitors and virus coded dna polymerase inhibitors"></PatentFamily><PatentFamily id="1807759" number="WO-2005069880" title="Modulation of LINE-1 reverse transcriptase"></PatentFamily><PatentFamily id="1829885" number="WO-09422480" title="HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS"></PatentFamily><PatentFamily id="1836932" number="WO-2006128328" title="A process for preparing didanosine"></PatentFamily><PatentFamily id="1896427" number="CN-100415211" title="AIDS drug didanosine granule composition and its preparation method"></PatentFamily><PatentFamily id="1902822" number="WO-00189509" title="A method of treating residual HIV-1 disease"></PatentFamily><PatentFamily id="1906862" number="WO-09523610" title="Pharmaceutical composition containing thymoctonan and AZT."></PatentFamily><PatentFamily id="2020087" number="WO-09740833" title="HIV protease inhibitors useful for the treatment of AIDS."></PatentFamily><PatentFamily id="202542" number="WO-2004078993" title="Process for preparing dideoxyinosine using adenosine deaminase enzyme"></PatentFamily><PatentFamily id="2049760" number="WO-2008131506" title="Mucoadhesive granules containing chitosan nano- and/or microspheres and the process of manufacture"></PatentFamily><PatentFamily id="2053894" number="US-20080187561" title="Enteric coated didanosine compositions having a subcoat"></PatentFamily><PatentFamily id="2068193" number="CN-101199542" title="Didanosine dispersing tablet and preparation method thereof"></PatentFamily><PatentFamily id="2197635" number="WO-2005011737" title="Pharmaceutical combinations and formulations with improved stability"></PatentFamily><PatentFamily id="2244469" number="WO-09955370" title="Methods for reducing HIV viral load by administering GM-CSF and antiretroviral agents."></PatentFamily><PatentFamily id="2281095" number="WO-2007123868" title="Organic thiophosphate antiretroviral agents"></PatentFamily><PatentFamily id="230111" number="IN-200600979" title="Pharmaceutical composition comprises enteric coated didanosine having subcoat"></PatentFamily><PatentFamily id="2307133" number="EP-00206497" title="Process for the preparation of therapeutic nucleosides."></PatentFamily><PatentFamily id="2342153" number="US-20090203636" title="Prevention and treatment of cancer and other diseases"></PatentFamily><PatentFamily id="2371593" number="WO-09517899" title="Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread."></PatentFamily><PatentFamily id="238106" number="WO-09118611" title="Diagnosis and treatment of viral hepatitis."></PatentFamily><PatentFamily id="2403778" number="WO-2012156086" title="Methods for improving and managing nucleoside reverse-transcriptase inhibition based treatment"></PatentFamily><PatentFamily id="2403855" number="WO-2012156083" title="Methods using transformed yeast cells for improving and managing nucleoside reverse-transcriptase inhibition based treatment"></PatentFamily><PatentFamily id="281630" number="WO-2005017189" title="Neural cell assay"></PatentFamily><PatentFamily id="2859265" number="CN-104211746" title="One of removing synthesis method of didanosine"></PatentFamily><PatentFamily id="3211626" number="IN-200502809" title="High drug load enteric coated pharmaceutical composition useful for treating patients infected with hiv, comprises core comprising inert nucleus and drug layer comprising didanosine surrounding inert nucleus, and enteric coating"></PatentFamily><PatentFamily id="3424317" number="CN-106008216" title="Pharmaceutical composition of didanosine and its application in biomedicine"></PatentFamily><PatentFamily id="3481605" number="WO-2016201566" title="Systems and methods of selecting compounds with reduced risk of cardiotoxicity using herg models"></PatentFamily><PatentFamily id="3481608" number="WO-2016201575" title="Systems and methods for predicting cardiotoxicity of molecular parameters of a compound based on machine learning algorithms"></PatentFamily><PatentFamily id="3837107" number="CN-107286212" title="A high-purity didanosine impurity of preparation method"></PatentFamily><PatentFamily id="394499" number="WO-00045844" title="Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous HIV"></PatentFamily><PatentFamily id="509725" number="WO-2006054175" title="Stable dosage forms of acid labile drug"></PatentFamily><PatentFamily id="52206" number="WO-2005025552" title="Protein binding compounds"></PatentFamily><PatentFamily id="54087" number="WO-09109605" title="Treatment of human retroviral infections with 2`,3`-dideoxyinosine."></PatentFamily><PatentFamily id="541790" number="WO-00003696" title="Enteric Coated Pharmaceutical Tablet And Method Of Manufacturing"></PatentFamily><PatentFamily id="595772" number="WO-2012031008" title="Cancer-related biological materials in microvesicles"></PatentFamily><PatentFamily id="648118" number="WO-2006125166" title="Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer"></PatentFamily><PatentFamily id="663539" number="WO-2010135918" title="Didanosine precursor drug and its preparation method"></PatentFamily><PatentFamily id="672093" number="WO-2011061302" title="Novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)"></PatentFamily><PatentFamily id="717831" number="WO-2007004230" title="A novel process for the preparation of didanosine using novel intermediates"></PatentFamily><PatentFamily id="771187" number="EP-01550665" title="A process for the production of purine nucleoside compounds"></PatentFamily><PatentFamily id="786811" number="WO-2009063320" title="Solid pharmaceutical composition of didanosine"></PatentFamily><PatentFamily id="819842" number="WO-2011061303" title="Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (HIV)"></PatentFamily><PatentFamily id="834411" number="EP-00524579" title="Improved oral dosing formulations of dideoxy purine nucleosides."></PatentFamily><PatentFamily id="837479" number="WO-09842349" title="Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread."></PatentFamily><PatentFamily id="848895" number="WO-2008015686" title="Stable multiparticulate formulations of didanosine"></PatentFamily><PatentFamily id="85969" number="WO-08701284" title="Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine"></PatentFamily><PatentFamily id="870403" number="WO-09533464" title="Retroviral protease inhibitor combinations."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>25</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>19</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>6</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenyang Pharmaceutical University" id="1004998"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alt Solutions Inc" id="1015438"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Blanver Farmoquimica Ltda" id="1030148"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Tiantai Aurisco Pharmaceutical Co Ltd" id="1057544"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Modern Pharmaceutical Engineering Research Center Co Ltd" id="1070238"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuhan National Pharmaceutical Technology Co Ltd" id="1073101"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AmiKana.Biologics" id="1075447"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zibo Huaao Chemical Co Ltd" id="1075865"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Meheco Co Ltd" id="1080978"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ajinomoto Co Inc" id="13794"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akzo Nobel NV" id="13802"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fundacao Oswaldo Cruz (Fiocruz)" id="16154"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gilead Sciences Inc" id="16450"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Calgary" id="20548"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emory University" id="20573"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Florida" id="20575"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Hawaii" id="20591"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Maryland" id="20611"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Thomas Jefferson University" id="20685"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vical Inc" id="20743"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>13</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aguettant SA" id="21898"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hemispherx Biopharma Inc" id="22879"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eberhard Karls Universität Tübingen" id="23358"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universidade Estadual de Campina" id="24983"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Research Institute for Genetic and Human Therapy" id="25098"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kagoshima University" id="25232"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PhotoCure ASA" id="25703"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lovelace Respiratory Research Institute" id="25948"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vectura Group plc" id="29998"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chimerix Inc" id="30079"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aurobindo Pharma Ltd" id="30215"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bio-Techne Corp" id="DOL1000125"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>